CFO changes at Biocryst, Xenon, Century, Pyxis

Rare disease company Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) named Babar Ghias CFO and head of corporate development. He was most recently CFO of CAR T cell therapy developer Avencell Therapeutics Inc.; he has also held executive roles at Castle Creek Biosciences Inc., Paragon Biosciences and Marathon Pharmaceuticals LLC.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) disclosed the resignation of CFO Sherry Aulin on June 30. President and CEO Ian Mortimer will fill the role on an interim basis...